The estimated Net Worth of Michael Graves is at least $386 millier dollars as of 27 October 2023. Mr. Graves owns over 9,360 units of Eagle Pharmaceuticals Inc stock worth over $38,643 and over the last 10 years he sold EGRX stock worth over $0. In addition, he makes $347,261 as Independent Chairman of the Board at Eagle Pharmaceuticals Inc.
Michael has made over 2 trades of the Eagle Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 9,360 units of EGRX stock worth $46,238 on 27 October 2023.
The largest trade he's ever made was exercising 9,360 units of Eagle Pharmaceuticals Inc stock on 27 October 2023 worth over $46,238. On average, Michael trades about 648 units every 174 days since 2014. As of 27 October 2023 he still owns at least 10,360 units of Eagle Pharmaceuticals Inc stock.
You can see the complete history of Mr. Graves stock trades at the bottom of the page.
Michael Graves serves as Independent Chairman of the Board of the Company. Mr. Graves joined the board of directors of RiboCor, Inc. and in December 2011, Mr. Graves was appointed chairman of the board of directors of Nanocopoeia, Inc., both private pharmaceutical companies. From May 2007 to July 2011, Mr. Graves served as the chief executive officer and president of Paddock Laboratories, Inc., a pharmaceutical company engaged in the manufacture, distribution and marketing of bioequivalent generic pharmaceuticals. From September 2005 to November 2006, Mr. Graves served as president of the generic products division at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals. While at Par, Mr. Graves oversaw the strategy development of Par's generic pharmaceutical business. Beginning in 1998, Mr. Graves served as director of marketing and sales operations of Par, and in 2004, Mr. Graves was promoted to senior vice president of corporate development and strategic planning. Mr. Graves served in this position until his promotion to president of the generic products division in September 2005. Mr. Graves holds a B.S. from State University College of New York at Buffalo. Our Board believes that Mr. Graves' extensive experience in marketing, sales, business development and operations qualifies him to serve on our Board.
As the Independent Chairman of the Board of Eagle Pharmaceuticals Inc, the total compensation of Michael Graves at Eagle Pharmaceuticals Inc is $347,261. There are 4 executives at Eagle Pharmaceuticals Inc getting paid more, with Scott Tarriff having the highest compensation of $7,883,700.
Michael Graves is 57, he's been the Independent Chairman of the Board of Eagle Pharmaceuticals Inc since 2016. There are 6 older and 4 younger executives at Eagle Pharmaceuticals Inc. The oldest executive at Eagle Pharmaceuticals Inc is Steven Ratoff, 77, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE, NJ, 07677.
Over the last 11 years, insiders at Eagle Pharmaceuticals Inc have traded over $188,911,314 worth of Eagle Pharmaceuticals Inc stock and bought 1,029,065 units worth $16,655,732 . The most active insiders traders include Executive Capital Lphec Man..., Douglas L Braunstein et Investments Iv, L.P.Pro Que.... On average, Eagle Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $193,721. The most recent stock trade was executed by Scott Tarriff on 1 November 2023, trading 21,619 units of EGRX stock currently worth $299,207.
Eagle Pharmaceuticals Inc executives and other stock owners filed with the SEC include: